Atlas Trials

A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease

Clinical trial NCT00679341 · COMPLETED

Trial details

NCT number
NCT00679341
Sponsor
Hoffmann-La Roche
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2008-09-01
Primary completion
2010-11-01
Enrollment
137

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.